CEACAM5-Targeted Immuno-PET in Androgen Receptor–Negative Prostate Cancer
Journal of Nuclear Medicine · 2024
DOI: 10.2967/jnumed.123.267107 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2024. Verfasst von Cinzia Imberti und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Positron-Emission Tomography, Receptors, Androgen, GPI-Linked Proteins. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
The incidence of androgen receptor (AR)-negative (AR-) prostate cancer, including aggressive neuroendocrine prostate cancer (NEPC), has more than doubled in the last decade, but its timely diagnosis is difficult as it lacks typical prostate cancer hallmarks. The carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) has recently been identified as an upregulated surface antigen in NEPC. We developed an immuno-PET agent targeting CEACAM5 and evaluated its ability to delineate AR- prostate cancer in vivo.
Methods
CEACAM5 expression was evaluated in a panel of prostate cancer cell lines by immunohistochemistry and Western blotting. The CEACAM5-targeting antibody labetuzumab was conjugated with the chelator desferrioxamine (DFO) and radiolabeled with 89Zr. The in vivo distribution of the radiolabeled antibody was evaluated in xenograft prostate cancer models by PET imaging and ex vivo organ distribution.
Results
The NEPC cell line H660 exhibited strong CEACAM5 expression, whereas expression was limited in the AR- cell lines PC3 and DU145 and absent in the AR-positive cell line LNCaP. [89Zr]Zr-DFO-labetuzumab imaging was able to clearly delineate both neuroendocrine H660 xenografts and AR- DU145 in vivo but could not detect the AR-positive xenograft LNCaP.
Conclusion
Immuno-PET imaging with [89Zr]Zr-DFO-labetuzumab is a promising diagnostic tool for AR- prostate cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Pharmacology, Weill Cornell Medicine, New York, New York.
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Korea.
- Department of Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Imberti, C., De Gregorio, R., Korsen, J. A., Hoang, T. T., Khitrov, S., Kalidindi, T., Nandakumar, S., Park, J., Zaidi, S., Pillarsetty, N. V. K., & Lewis, J. S. (2024). CEACAM5-Targeted Immuno-PET in Androgen Receptor–Negative Prostate Cancer. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.123.267107
Vancouver
Imberti C, De Gregorio R, Korsen JA, Hoang TT, Khitrov S, Kalidindi T, et al. CEACAM5-Targeted Immuno-PET in Androgen Receptor–Negative Prostate Cancer. Journal of Nuclear Medicine. 2024. doi:10.2967/jnumed.123.267107
BibTeX
@article{Imberti2024,
author = {Imberti, Cinzia and De Gregorio, Roberto and Korsen, Joshua A and Hoang, Tran T and Khitrov, Samantha and Kalidindi, Teja and Nandakumar, Subhiksha and Park, Jooyoung and Zaidi, Samir and Pillarsetty, Naga Vara Kishore and Lewis, Jason S},
title = {CEACAM5-Targeted Immuno-PET in Androgen Receptor–Negative Prostate Cancer},
journal = {Journal of Nuclear Medicine},
year = {2024},
doi = {10.2967/jnumed.123.267107}
}
EUVIMED